Trial Profile

US Selumetinib Registry

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selumetinib (Primary)
Indications Neurofibromatosis 1; Plexiform neurofibroma
Focus Adverse reactions; Therapeutic Use
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

04 Apr 2025 Status changed from recruiting to discontinued due to sponsors decision.
08 Aug 2023 Status changed from not yet recruiting to recruiting.
27 Jun 2023 Planned initiation date changed from 15 Mar 2023 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com